ArticlePloS one2017
Numerical modeling of nanodrug distribution in tumors with heterogeneous vasculature.
Article in PloS one, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed.
- A Spatiotemporal Image-Guided Model of Radiopharmaceutical Transport in Heterogeneous Vasculature Prostate Tumor: A Computational Analysis of Key Parameters in Lutetium-177 PSMA Therapy.Annals of biomedical engineering · 2026Article
- Finite Element Simulation of Interstitial-Lymphatic Fluid Flow and Nanodrug Transport in a Solid Tumor: An Intratumoral Injection Approach.BME frontiers · 2025Article
- Emerging resistome diversity in clinical Vibrio cholerae strains revealing their role as potential reservoirs of antimicrobial resistance.Molecular biology reports · 2024Article
- Gut microbiome as therapeutic target for diabesity management: opportunity for nanonutraceuticals and associated challenges.Drug delivery and translational research · 2024Review
- Multi-Scale and Multi-Physics Models of the Transport of Therapeutic/Diagnostic Cancer Agents.Cancers · 2023Article
- Computational Multi-Scale Modeling of Drug Delivery into an Anti-Angiogenic Therapy-Treated Tumor.Cancers · 2023Article
- Image-Based Modeling of Drug Delivery during Intraperitoneal Chemotherapy in a Heterogeneous Tumor Nodule.Cancers · 2023Article
- Multiscale Modelling of Nanoparticle Distribution in a Realistic Tumour Geometry Following Local Injection.Cancers · 2022Article
- Modelling of Nanoparticle Distribution in a Spherical Tumour during and Following Local Injection.Pharmaceutics · 2022Article
- Numerical Investigation on the Anti-Angiogenic Therapy-Induced Normalization in Solid Tumors.Pharmaceutics · 2022Article
- Mathematical Modeling of Targeted Drug Delivery Using Magnetic Nanoparticles during Intraperitoneal Chemotherapy.Pharmaceutics · 2022Article
- Intracellular vesicle entrapment of nanobubble ultrasound contrast agents targeted to PSMA promotes prolonged enhancement and stabilityNanotheranostics · 2022Article
- Computational Modeling of Combination of Magnetic Hyperthermia and Temperature-Sensitive Liposome for Controlled Drug Release in Solid Tumor.Pharmaceutics · 2021Article
- Computational modeling of PET tracer distribution in solid tumors integrating microvasculature.BMC biotechnology · 2021Article
- Evaluation of solid tumor response to sequential treatment cycles via a new computational hybrid approach.Scientific reports · 2021Article
- Identification and mapping of quantitative trait loci for resistance to Liriomyza trifolii in romaine lettuce cultivar 'Valmaine'.Scientific reports · 2021Article
- Enhanced Drug Delivery to Solid Tumors via Drug-Loaded Nanocarriers: An Image-Based Computational Framework.Frontiers in oncology · 2021Article
- Validation of MRI quantitative susceptibility mapping of superparamagnetic iron oxide nanoparticles for hyperthermia applications in live subjects.Scientific reports · 2020Article
- Numerical modeling of high-intensity focused ultrasound-mediated intraperitoneal delivery of thermosensitive liposomal doxorubicin for cancer chemotherapy.Drug delivery · 2019Article
- Mixture theory modeling for characterizing solute transport in breast tumor tissues.Journal of biological engineering · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The distribution and accumulation of nanoparticle dosage in a tumor are important in evaluating the effectiveness of cancer treatment. The cell survival rate can quantify the therapeutic effect, and the survival rates after multiple treatments are helpful to evaluate the efficacy of a chemotherapy plan. We developed a mathematical tumor model based on the governing equations describing the fluid flow and particle transport to investigate the drug transportation in a tumor and computed the resulting cumulative concentrations. The cell survival rate was calculated based on the cumulative concentration. The model was applied to a subcutaneous tumor with heterogeneous vascular distributions. Various sized dextrans and doxorubicin were respectively chosen as the nanodrug carrier and the traditional chemotherapeutic agent for comparison. The results showed that: 1) the largest nanoparticle drug in the current simulations yielded the highest cumulative concentration in the well vascular region, but second lowest in the surrounding normal tissues, which implies it has the best therapeutic effect to tumor and at the same time little harmful to normal tissue; 2) on the contrary, molecular chemotherapeutic agent produced the second lowest cumulative concentration in the well vascular tumor region, but highest in the surrounding normal tissue; 3) all drugs have very small cumulative concentrations in the tumor necrotic region, where drug transport is solely through diffusion. This might mean that it is hard to kill tumor stem cells hiding in it. The current model indicated that the effectiveness of the anti-tumor drug delivery was determined by the interplay of the vascular density and nanoparticle size, which governs the drug transport properties. The use of nanoparticles as anti-tumor drug carriers is generally a better choice than molecular chemotherapeutic agent because of its high treatment efficiency on tumor cells and less damage to normal tissues.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.